A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|120|11|1647-1655

ISSN: 0008-543x

Source: CANCER, Vol.120, Iss.11, 2014-06, pp. : 1647-1655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract